Study or Subgroup	CRT Events	Total	CT/S Events	Total	Weight	Odds Ratio M-H, Random, 95% CI	Odds Ratio M-H, Random, 95% CI
CRT+S vs CT+S							
Klevebro, 2016	68	90	58	91	9.3%	1.76 [0.92, 3.35]	
Klevebro,2016	238	249	160	187	8.6%	3.65 [1.76, 7.57]	
Mariette, 2014	76	81	82	89	5.3%	1.30 [0.40, 4.26]	
Nygaard,1992	26	53	22	56	8.3%	1.49 [0.70, 3.18]	
Spicer, 2016	99	100	87	114	2.5%	30.72 [4.09, 230.82]	
Stahl,2009	43	60	41	59	8.1%	1.11 [0.50, 2.44]	
Subtotal (95% CI)		633		596	42.0%	2.11 [1.15, 3.86]	
Total events	550		450				

Heterogeneity: Tau² = 0.34; Chi² = 13.86, df = 5 (P = 0.02); I² = 64%
Test for overall effect: Z = 2.41 (P = 0.02)

CRT+S vs S							
Bosset,1997	112	143	94	139	10.3%	1.73 [1.01, 2.95]	
Burmeister,2005	103	128	76	128	10.0%	2.82 [1.61, 4.94]	
Klevebro, 2016	238	249	341	411	9.2%	4.44 [2.30, 8.57]	
Le Prise,1994	35	41	38	45	5.4%	1.07 [0.33, 3.51]	
Nygaard,1992	26	53	15	50	7.9%	2.25 [1.00, 5.05]	
Urba, 2001	45	47	45	50	3.3%	2.50 [0.46, 13.56]	
van Hagen,2012	148	161	111	161	9.2%	5.13 [2.66, 9.90]	
Walsh, 1996	13	55	0	55	1.4%	35.26 [2.04, 610.04]	
Zhao,2015	36	36	32	40	1.3%	19.09 [1.06, 343.90]	
Subtotal (95% CI)		913		1079	58.0%	2.96 [1.93, 4.55]	
Total events	756		752				

Heterogeneity: Tau² = 0.18; Chi² = 16.22, df = 8 (P = 0.04); I² = 51%
Test for overall effect: Z = 4.97 (P < 0.00001)

Total (95% CI)		1546		1675	100.0%	2.56 [1.79, 3.64]	
Total events	1306		1202				

Heterogeneity: Tau² = 0.24; Chi² = 33.07, df = 14 (P = 0.003); I² = 58%
Test for overall effect: Z = 5.20 (P < 0.00001)
Test for subgroup differences: Chi² = 0.81, df = 1 (P = 0.37), I² = 0%

Figure S1 The subgroup meta-analysis of R0 resection rate in neoadjuvant chemoradiation (CRT) plus surgery (S) compared with neoadjuvant chemotherapy (CT) plus surgery (S) or surgery alone (S)

Table S1 Quality evaluation of included studies using NOS

Study	Selection				Comparability	Exposure			
	Adequate definition of cases	Representativeness of cases	Selection of controls	Definition of controls	Comparability of cases and controls on the basis of the design or analysis	Ascertainment of exposure	Same method of ascertainment for cases and controls	Nonresponse rate	Total scores
Bosset,1997	*	*	*	*	*	*	*	0	7
Burmeister,2005	*	*	*	*	*	*	*	*	8
Klevebro, 2016 (9)	*	*	*	*	*	*	*	*	8
Klevebro,2016 (10)	*	*	*	*	*	*	*	*	8
Le Prise,1994	*	*	*	*	*	0	*	0	6
Mariette, 2014	*	*	*	*	*	0	*	0	6
Natsugoe,2006	*	*	*	*	*	0	0	0	5
Nygaard,1992	*	*	*	*	0	0	*	0	5
Shapiro, 2015	*	*	*	*	*	0	*	0	6
Spicer, 2016	*	*	*	*	0	0	0	*	5
Stahl,2009	*	*	*	*	*	0	*	*	7
Stahl,2017	*	*	*	*	*	0	*	*	7
Tepper,2008	*	*	*	*	*	*	*	*	8
Urba, 2001	*	*	*	*	*	0	*	0	6
van Hagen,2012	*	*	*	*	*	*	*	0	7
Walsh, 1996	*	*	*	*	*	0	*	*	7
Zhao,2015	*	*	*	*	*	0	*	*	7

Abbreviations:* indicates a score of 1.

Table S2 Meta-analysis of subgroup on overall survival in adenocarcinoma for neoadjuvant chemoradiation (CRT) plus surgery (S) compared with neoadjuvant chemotherapy (CT) plus surgery (S) or surgery alone (S)

Overall survival	No.of studies	No.of patients				Model for meta-analysis	RR(95%CI)	I^2(%)	P for heterogeneity
		CRT+S		CT+S/S					
		event	total	event	total				
CRT+S vs CT+S									
1 yr	5[9-10,15-17]	326	509	350	477	R	0.93 (0.77, 1.14)	82%	0.0002
2 yr	5[9-10,15-17]	244	509	203	477	F	1.14 (0.99, 1.31)	23%	0.27
3 yr	5[9-10,15-17]	161	509	131	477	F	1.16 (0.96, 1.41)	49%	0.1
5 yr	4[10,15-17]	82	444	55	411	R	1.43 (0.90, 2.28)	51%	0.1
CRT+S vs S									
1 yr		412	628	524	746	R	0.98 (0.79, 1.23)	88%	< 0.00001
2 yr	5[8,10,14,20-21]	322	628	351	746	R	1.13 (0.93, 1.38)	64%	0.03
3 yr		228	628	252	746	R	1.14 (0.83, 1.57)	72%	0.006
5 yr		131	628	124	746	R	1.39 (0.86, 2.25)	69%	0.01

Abbreviations:CRT:chemoradiation;CT:chemotherapy;S:surgery;RR: relative risk;CI: confidence interval;F:fixed model;R: random model